Single-dose Treatment of Uncomplicated Gonococcal Urethritis

Publisher Website
Google Scholar
Abstract
Cefonicid, a parenterally administered semisynthetic cephalosporin, produces high and sustained serum levels in humans. It is active in vitro against Neisseria gonorrhoeae, including B-lactamase-producing strains. Therefore, the efficacy of cefonicid in treatment of men with uncomplicated gonococcal urethritis was evaluated in a 2-phase study. Initially, 58 men were treated i.m. with 1 g of cefonicid. There were 4 failures among the 50 patients who could be evaluated. In the 2nd phase (a double-blind study), 57 men received either 1.0 g of cefonicid or 4.8 .times. 106 U of procaine penicillin G plus 1.0 g of probenecid. Among 17 men treated with penicillin, there were 2 failures; among the 33 cefonicid-treated patients, there was only 1 failure. Thus, 78 (94%) of 83 patients receiving cefonicid were cured. Of the 85 pretreatment and 4 posttreatment isolates tested, 31 were inhibited by < 0.0625 .mu.g of penicillin/ml and 87 were inhibited by < 1.0 .mu.g/ml. Of the 89 isolates, 28 were inhibited by < 0.0625 .mu.g of cefonicid/ml and 88, by < 1.0 .mu.g of cefonicid/ml. Evidently, 1.0 g of cefonicid given i.m. is effective therapy for uncomplicated gonococcal urethritis.

This publication has 1 reference indexed in Scilit: